Project Grant R01HL185226
Award Date 8/15/26
Completion Date 5/31/31
Dollars Obligated $389K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Washington University $169,140 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support immuno-metabolic research into chronic rejection after lung transplant. The funding supports investigation of the mechanistic drivers of bronchiolitis obliterans syndrome (BOS), a form of chronic rejection that is the major cause of death one year after lung transplant. The principal investigator, a lung transplant...
- The National Heart, Lung, and Blood Institute awarded The Washington University $1.902 million on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and correct immune-epithelial pathways underlying chronic muco-obstructive lung disease triggered by viral infection, allergen, smoke, or pollution exposure. The research identifies and characterizes a distinct subset of basal epithelial stem cells (basal-ESCs) that drive muco-obstructive disease phenotypes...
- The National Heart, Lung, and Blood Institute awarded The Washington University $233,250 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 15, 2026, to investigate the mechanisms by which mycophenolic acid (MPA) induces neutropenia in lung transplant recipients. The research examines how MPA influences neutrophil development, survival, and effector function, with a hypothesis that MPA disrupts metabolic pathways—particularly glycolysis—and alters gene expression during...
- The National Heart, Lung, and Blood Institute awarded The Feinstein Institutes for Medical Research $586,866 on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the protective role of B-1a cells in acute lung injury and to evaluate a novel therapeutic compound. The project examines the mechanisms by which B-1a cells mitigate acute lung injury and acute respiratory distress syndrome, conditions frequently triggered by sepsis or ischemia-reperfusion...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Washington University $635,247 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of resolution-phase neutrophils in acute respiratory distress syndrome (ARDS) recovery. The project tests the hypothesis that neutrophils activate counter-regulatory mechanisms, including expression of 15-lipoxygenase (15-LO), in lung tissue following acute injury to...
- The National Heart, Lung, and Blood Institute awarded The Washington University $680,379 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of sphingolipid biosynthesis during lung infection, specifically examining how SPTLC2, an essential enzyme subunit in sphingolipid synthesis, affects survival during Mycobacterium tuberculosis infection in CD11C+ lung macrophages and dendritic cells. The project addresses immune response mechanisms...
- The National Heart Lung and Blood Institute awarded Northwestern University $654,762 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory T cell mechanisms limiting persistent inflammation during recovery from viral pneumonia. The award funds research into how FOXP3+ regulatory T cells orchestrate lung repair after viral pneumonia through expression of suppressive mediators, particularly the anti-inflammatory cytokine interleukin-10. The...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $787,297 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 4, 2026. The award funds research into vascular dysfunction and lung allograft health, specifically investigating the mechanisms of primary graft dysfunction (PGD)—an ischemia-reperfusion injury that occurs in approximately 35 percent of lung transplants. The research examines how inflammasome-mediated pyroptosis and endothelial...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Washington University $761,782 under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, with completion targeted for July 31, 2029. This project grant funds basic and translational research investigating the loss of cilia maintenance mechanisms in acquired and genetic lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The...
- The National Heart, Lung, and Blood Institute awarded Northwestern University a project grant of $793,976 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate bone morphogenetic protein and connexin40 signaling as regulators of endothelial quiescence in lung transplantation. The research addresses primary graft dysfunction, an acute lung injury driven by ischemia-reperfusion injury that limits lung transplantation success. The project will...